Tris Pharma
Develops and sells medicines for ADHD and neurological disorders.
Company facts
- Founded
- 2000
- Employees
- 500
- Headquarters
- United States
- CEO
- Ketan Mehta
- Type
- Private
- Funding
- Grant · $16.6M · 2023
- Subsidiaries
- Park Therapeutics, NextWave Pharmaceuticals
About
At Tris Pharma, we are inspired by and dedicated to making a profound impact on the lives of patients around the world. We are a biopharmaceutical company that focuses on innovating therapies with real impact, specifically targeting ADHD, pain, addiction, and diseases of the central nervous system (CNS). Through groundbreaking technology, we are revolutionizing treatment in these areas. Utilizing our industry-leading capabilities and our proprietary LiquiXR® platform, we develop and deliver patient-friendly therapeutics that maximize benefits and offer unique solutions not available from existing therapies. Our commitment to innovation aims to tackle some of the most persistent therapeutic challenges and is reflected in our expanding portfolio of more than a dozen approved medicines and a strong pipeline of investigational therapies designed to meet the unmet needs of patients globally.